TZIELD
Biological
SANOFI-AVENTIS U.S. LLC
Total Payments
$7.7M
Transactions
35,296
Doctors
16,262
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $5.8M | 27,724 | 14,407 |
| 2023 | $1.9M | 7,520 | 4,054 |
| 2022 | $2,897 | 52 | 52 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.8M | 269 | 36.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.6M | 1,120 | 34.0% |
| Food and Beverage | $1.1M | 32,592 | 14.1% |
| Consulting Fee | $742,866 | 136 | 9.7% |
| Travel and Lodging | $420,874 | 1,174 | 5.5% |
| Space rental or facility fees (teaching hospital only) | $8,850 | 5 | 0.1% |
Payments by Type
General
$4.9M
35,027 transactions
Research
$2.8M
269 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Multicenter, Multinational Extension of Study PRV-031-001 to Evaluate the Long-Term Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adolescents With Recent-Onset Type 1 Diabetes Mellitus | SANOFI US SERVICES INC. | $2.7M | 20 |
| Single Arm, Open-label Study to Assess the Safety and Pharmacokinetics of a 14-day Regimen of Teplizumab in Pediatric Stage 2 Type 1 Diabetes | SANOFI-AVENTIS U.S. LLC | $31,725 | 0 |
| Single Arm, Open-label Study to Assess the Safety and Pharmacokinetics of a 14-day Regimen of Teplizumab in Pediatric Stage 2 Type 1 Diabetes (Participants With at Least Two Autoantibodies and Dysglycemia) | SANOFI US SERVICES INC. | $29,736 | 0 |
| Single Arm, Open-label Study to Assess the Safety and Pharmacokinetics of a 14-day Regimen of Teplizumab in Pediatric Stage 2 Type 1 Diabetes (Participants With at Least Two Autoantibodies and Dysglycemia) | SANOFI-AVENTIS U.S. LLC | $13,500 | 0 |
| An Open-Label Study to Evaluate the Safety of Teplizumab (PRV-031) in At-Risk Relatives Who Develop Type 1 Diabetes | SANOFI-AVENTIS U.S. LLC | $12,925 | 0 |
Top Doctors Receiving Payments for TZIELD — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Pediatric Endocrinology | Nashville, TN | $26,790 | 18 |
| , MD | Endocrinology, Diabetes & Metabolism | West Lafayette, IN | $25,729 | 17 |
| , MD | Internal Medicine | Miami, FL | $23,127 | 6 |
| , M.D | Internal Medicine | Camp Springs, MD | $22,320 | 31 |
| , MD | Pediatric Endocrinology | Atlanta, GA | $21,725 | 22 |
| , MSN,FNP-BC | Primary Care | Wheeling, WV | $21,706 | 43 |
| , M.D | Internal Medicine | Bayside, NY | $20,517 | 26 |
| , DNP, CPNP-PC | Pediatrics | Savannah, GA | $20,110 | 25 |
| , MD | Pediatric Endocrinology | Sioux Falls, SD | $19,784 | 6 |
| , MD | Endocrinology, Diabetes & Metabolism | San Antonio, TX | $18,580 | 38 |
| , D.O | Endocrinology, Diabetes & Metabolism | Frederick, MD | $18,532 | 22 |
| , PA | Dietitian, Registered | Little Rock, AR | $18,041 | 31 |
| , MD | Pediatric Endocrinology | Aurora, CO | $17,502 | 10 |
| , MD | Endocrinology, Diabetes & Metabolism | Flemington, NJ | $17,081 | 20 |
| , MD | Endocrinology, Diabetes & Metabolism | Joliet, IL | $16,970 | 22 |
| , M.D | Pediatric Endocrinology | Santurce, PR | $16,736 | 11 |
| , MD | Endocrinology, Diabetes & Metabolism | Somers Point, NJ | $16,665 | 19 |
| , MD | Endocrinology, Diabetes & Metabolism | Hammond, LA | $16,026 | 15 |
| , M.D | Pediatrics | San Francisco, CA | $15,911 | 10 |
| , MD FACE | Endocrinology, Diabetes & Metabolism | Elmhurst, IL | $14,894 | 16 |
| , MD | Pediatrics | Hoffman Estates, IL | $13,952 | 14 |
| , M.D | Endocrinology, Diabetes & Metabolism | Torrington, CT | $13,448 | 21 |
| , MD | Pediatrics | Madera, CA | $13,401 | 18 |
| , MD | Pediatric Endocrinology | Saint Petersburg, FL | $12,623 | 2 |
| , CRNP | Adult Health | Riverdale, MD | $11,738 | 29 |
Ad
Manufacturing Companies
- SANOFI-AVENTIS U.S. LLC $4.9M
- SANOFI US SERVICES INC. $2.8M
- GENZYME CORPORATION $82.59
- SANOFI PASTEUR INC. $27.39
Product Information
- Type Biological
- Total Payments $7.7M
- Total Doctors 16,262
- Transactions 35,296
About TZIELD
TZIELD is a biological associated with $7.7M in payments to 16,262 healthcare providers, recorded across 35,296 transactions in the CMS Open Payments database. The primary manufacturer is SANOFI-AVENTIS U.S. LLC.
Payment data is available from 2022 to 2024. In 2024, $5.8M was paid across 27,724 transactions to 14,407 doctors.
The most common payment nature for TZIELD is "Unspecified" ($2.8M, 36.7% of total).
TZIELD is associated with 5 research studies, including "A Multicenter, Multinational Extension of Study PRV-031-001 to Evaluate the Long-Term Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adolescents With Recent-Onset Type 1 Diabetes Mellitus" ($2.7M).